IRWD
IRONWOOD PHARMACEUTICALS INC
$3.29
-0.60%
$541.6M
No data for this timeframe.
Vol
Market Cap$541.6M
Cap SizeSmall Cap
Inst. Holders8 funds
Inst. Value$152.0M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 7S
Insider Net $-$21.5M
SEC Reports5
Recent Activity
May 24, 2026
fda_pdufa
PDUFA: IRWD — LINZESS in functional constipation in patients 2 to 5 years of age — 2026-05-24
FDA target action date 2026-05-24 for IRWD (IRONWOOD PHARMACEUTICALS INC). Drug: LINZESS. Indication
May 19, 2026
Insider
Silver Ronald sold 25,000 shares
PFO & PAO @ $0.00 ($0.00)
May 13, 2026
SEC
IRWD CFO Gregory Martini resigned effective May 15, 2026, with Ronald Silver serving as interim CFO. The resignation is
8-K — Impact 6/10
May 7, 2026
SEC
Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS of $0.24 vs $0.07 consensus (+243%) and revenue o
8-K — Impact 7/10
Mar 17, 2026
Insider
DENNER ALEXANDER J sold 6,725,000 shares
Director @ $3.05 ($20.5M)
Mar 13, 2026
Insider
DENNER ALEXANDER J sold 4,451 shares
Director @ $0.00 ($0.00)
Feb 26, 2026
SEC
Six open-market share sales by three C-suite executives at Ironwood Pharmaceuticals (IRWD) over the past seven days tota
CLUSTER — Impact 6/10
Inst.
MORGAN STANLEY — ADD
739,685 shares ($2.5M)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$6.10 (Feb 2026)
Current $3.22
Low $3.70
Median $5.35
High $10.00
4 analysts
$3.70
$10.00
Analyst Ratings
2Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 26, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Jan 5, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Jan 5, 2026 | Citizens | UPGRADE | Market Perform → Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.28 ▼ -15.8% | $0.27 — $0.28 | 96% YoY | 2 |
| Next Q | $0.29 ▼ -25.0% | $0.29 — $0.29 | 21% YoY | 2 |
| Current FY | $1.09 ▼ -19.3% | $1.05 — $1.13 | 336% YoY | 2 |
| Next FY | $1.44 ▼ -1.1% | $1.26 — $1.74 | 32% YoY | 3 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $53.8M | — |
| BANK OF AMERICA CORP | $38.8M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $27.7M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $16.8M | ADD |
| TWO SIGMA INVESTMENTS, LP | $9.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | Silver Ronald | A | $0.00 |
| Mar 17, 2026 | DENNER ALEXANDER | SELL | $20.5M |
| Mar 13, 2026 | DENNER ALEXANDER | A | $0.00 |
| Mar 10, 2026 | Gaskins Tammi | A | $0.00 |
| Mar 10, 2026 | Shetzline Michael | A | $0.00 |
8 institutional holders with $152.0M total value (45,116,977 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15,958,196 | $53.8M | 35.4% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 11,521,660 | $38.8M | 25.5% | DOUBLED +248.3% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 8,204,973 | $27.7M | 18.2% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4,975,939 | $16.8M | 11.0% | ADD +34.2% |
| 5 | TWO SIGMA INVESTMENTS, LP | 2,853,205 | $9.6M | 6.3% | DOUBLED +124.1% |
| 6 | MORGAN STANLEY | 739,685 | $2.5M | 1.6% | ADD +55.0% |
| 7 | FMR LLC | 686,737 | $2.3M | 1.5% | ADD +58.2% |
| 8 | WELLS FARGO & COMPANY/MN | 176,582 | $595.1K | 0.4% | ADD +74.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 477,100 | 739,685 | +55.0% | $2.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 101,252 | 176,582 | +74.4% | $595.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 3,357,872 | 11,695,544 | +248.3% | $15.3M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 3,664,276 | 4,917,336 | +34.2% | $6.4M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 2,647,015 | 3,664,276 | +38.4% | $2.6M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,428,516 | 3,357,872 | +135.1% | $2.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 1,227,196 | 2,750,573 | +124.1% | $2.0M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,863,221 | 494,034 | -73.5% | $354.3K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,983,240 | 2,647,015 | +33.5% | $3.9M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 4,024,693 | 1,863,221 | -53.7% | $2.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 863,428 | 1,227,196 | +42.1% | $1.8M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 576,264 | 959,248 | +66.5% | $1.4M | 2025-Q1 |
| FMR LLC | ADD | 303,273 | 479,741 | +58.2% | $705.2K | 2025-Q1 |
| NORGES BANK | EXIT | 252,291 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | TRIM | 394,266 | 252,291 | -36.0% | $1.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 64,970 | 82,565 | +27.1% | $365.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,904,271 | — | $7.8M | 2024-Q3 |
7 unique insiders with 7 transactions. Net insider value: -$21.5M ($0.00 bought, $21.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | Silver Ronald | PFO & PAO | A | 25,000 | $0.00 | $0.00 |
| Mar 17, 2026 | DENNER ALEXANDER J | Director | SELL | 6,725,000 | $3.05 | $20.5M |
| Mar 13, 2026 | DENNER ALEXANDER J | Director | A | 4,451 | $0.00 | $0.00 |
| Mar 10, 2026 | Gaskins Tammi L | Chief Commercial Officer | A | 136,612 | $0.00 | $0.00 |
| Mar 10, 2026 | Shetzline Michael | SVP, CMO, Head-Res&Drug | A | 136,612 | $0.00 | $0.00 |
| Mar 10, 2026 | John Minardo | Chief Legal Officer | A | 136,612 | $0.00 | $0.00 |
| Mar 10, 2026 | MCCOURT Thomas A | Chief Executive Officer | A | 409,836 | $0.00 | $0.00 |
| Mar 10, 2026 | Silver Ronald | Principal Accounting Officer | A | 163,934 | $0.00 | $0.00 |
| Mar 10, 2026 | Martini Gregory S. | Chief Financial Officer | A | 136,612 | $0.00 | $0.00 |
| Feb 24, 2026 | John Minardo | Chief Legal Officer | SELL | 19,053 | $3.66 | $69.7K |
| Feb 24, 2026 | MCCOURT Thomas A | Chief Executive Officer | SELL | 103,526 | $3.66 | $378.9K |
| Feb 24, 2026 | Martini Gregory S. | Chief Financial Officer | SELL | 11,457 | $3.66 | $41.9K |
| Feb 23, 2026 | Martini Gregory S. | Chief Financial Officer | SELL | 10,487 | $3.81 | $40.0K |
| Feb 23, 2026 | John Minardo | Chief Legal Officer | SELL | 17,439 | $3.81 | $66.4K |
| Feb 23, 2026 | MCCOURT Thomas A | Chief Executive Officer | SELL | 94,757 | $3.81 | $361.0K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 1 mixed, 0 neutral. Avg impact: 6.2/10.
MIXED
8-K
6/10
IRWD CFO Gregory Martini resigned effective May 15, 2026, with Ronald Silver serving as interim CFO.
May 13, 2026
BULLISH
8-K
7/10
Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS of $0.24 vs $0.07 consensus (
May 7, 2026
BEARISH
CLUSTER
6/10
Six open-market share sales by three C-suite executives at Ironwood Pharmaceuticals (IRWD) over the
Feb 26, 2026
BEARISH
CLUSTER
7/10
Ironwood Pharmaceuticals CEO Thomas McCourt and CFO Gregory Martini collectively sold over $821,000
Feb 25, 2026
BEARISH
8-K
5/10
Ironwood Pharmaceuticals reported full-year 2025 revenue of $296 million, down from $351.4 million i
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 70% buy across 10 analysts — 2 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$6.10 mean target (Feb 2026)
$3.70 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $3.22 |
| Target Low | $3.70 |
| Target Mean | $6.10 |
| Target Median | $5.35 |
| Target High | $10.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.28 | $0.27 | $0.28 | 96.4% | -15.8% | 0↑ 1↓ | $0.1B | 38.0% | 2 |
| Next Q 2026-09-30 |
$0.29 | $0.29 | $0.29 | 20.8% | -25.0% | 0↑ 1↓ | $0.1B | -2.5% | 2 |
| Current FY 2026-12-31 |
$1.09 | $1.05 | $1.13 | 336.0% | -19.3% | 0↑ 1↓ | $0.5B | 55.1% | 2 |
| Next FY 2027-12-31 |
$1.44 | $1.26 | $1.74 | 32.1% | -1.1% | 0↑ 1↓ | $0.5B | 4.1% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.275 | |
| 7d ago | $0.327 | -0.052 |
| 30d ago | $0.327 | -0.052 |
| 60d ago | $0.327 | -0.052 |
| 90d ago | $0.255 | +0.020 |
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Jan 5, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 5, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Mar 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Feb 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Jan 1, 2026 | 0 | 0 | 6 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 24, 2026
fda_pdufa
PDUFA: IRWD — LINZESS in functional constipation in patients 2 to 5 years of age — 2026-05-24
FDA target action date 2026-05-24 for IRWD (IRONWOOD PHARMACEUTICALS INC). Drug: LINZESS. Indication: functional constipation in patients 2 to 5 years
May 22, 2026
short_volume
Short Volume: IRWD — 67.6% short (0.6M / 0.8M)
Short: 565,931 | Exempt: 805 | TRF Vol: 837,122 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: IRWD — 63.7% short (0.9M / 1.4M)
Short: 885,753 | Exempt: 414 | TRF Vol: 1,391,309 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: IRWD — 58.6% short (0.6M / 1.0M)
Short: 558,476 | Exempt: 19,043 | TRF Vol: 952,589 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: IRWD — 55.9% short (0.5M / 0.8M)
Short: 465,271 | Exempt: 3,333 | TRF Vol: 832,162 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
IRWD Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings_calendar
IRWD Q1 2026 Earnings Scheduled — 2026-05-05
May 5, 2026
short_volume
Short Volume: IRWD — 78.2% short (1.5M / 1.9M)
Short: 1,450,462 | Exempt: 4,611 | TRF Vol: 1,854,580 | Short Ratio: 78.2% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: IRWD — 66.5% short (0.9M / 1.4M)
Short: 911,588 | Exempt: 40 | TRF Vol: 1,370,187 | Short Ratio: 66.5% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: IRWD — 56.1% short (0.4M / 0.7M)
Short: 396,392 | Exempt: 0 | TRF Vol: 707,027 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
IRWD Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
short_volume
Short Volume: IRWD — 62.3% short (0.5M / 0.8M)
Short: 467,238 | Exempt: 3,511 | TRF Vol: 750,142 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: IRWD — 62.7% short (0.7M / 1.2M)
Short: 730,926 | Exempt: 0 | TRF Vol: 1,166,536 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: IRWD — 64.0% short (1.0M / 1.6M)
Short: 1,035,112 | Exempt: 2,643 | TRF Vol: 1,617,033 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_volume
Short Volume: IRWD — 59.1% short (0.7M / 1.2M)
Short: 710,477 | Exempt: 2,855 | TRF Vol: 1,202,109 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)